Brilinta ODT TM
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional. Always read the label. If symptoms persist see your healthcare professional.
Active ingredients: ticagrelor
Pack: Brilinta ODT 90 mg dispersible tablet, 56, blister pack
Brand name
(ARTG)
: BRILINTA ODT ticagrelor 90 mg orodispersible tablet blister packDownload the Consumer Medicine Information Leaflet
Download consumer medicine information leaflet (pdf) from the Therapeutic Goods Administration (TGA) website
What this medicine is used for
(ARTG)
BRILINTA, in combination with aspirin, is indicated for the prevention of atherothrombotic events (cardiovascular death, myocardial infarction and stroke) in adult patients with acute coronary syndromes (unstable angina [UA], non ST elevation Myocardial Infarction [NSTEMI] or ST elevation Myocardial Infarction [STEMI]) including patients managed medically, and those who are managed with percutaneous coronary intervention (PCI) or coronary artery by-pass grafting (CABG).
How to use this medicine
(ARTG)
This medicine contains one component only.
Component :
- Tablet, dispersible
- Oral
- White to pale pink, round, flat, bevelled edged orodispersible tablet with diameter 14 mm. Tablets are debossed with '90' above 'TI' on one side and plain on reverse.
Storage conditions
(ARTG)
- Store below 30 degrees Celsius
- Shelf lifetime is 3 Years.
Do I need a prescription ?
(ARTG)
These medicine packs are available from a pharmacist and requires a prescription. It is
- 56 tablets pack
Pregnant or planning a pregnancy ?
(AHT)
For the active ingredient ticagrelor
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems
